Literature DB >> 6202881

Characterization of a Rous sarcoma virus mutant defective in packaging its own genomic RNA: biochemical properties of mutant TK15 and mutant-induced transformants.

T Koyama, F Harada, S Kawai.   

Abstract

The accompanying paper (S. Kawai and T. Koyama , J. Virol. 51:147-153, 1984) describes the isolation and biological properties of a mutant, TK15 , derived from a Rous sarcoma virus mutant, tsNY68 . The cis-acting defect of the mutant is analyzed biochemically in this paper. TK15 virions released from virus-producing 15c (+) cells were deficient in viral genomic 39S RNA, although comparable amounts of viral RNAs were transcribed in 15c (+) and tsNY68 -infected cells. Analysis of provirus DNA occurring in 15c (+) cells suggested that the mutant genome had a deletion of ca. 250 bases near the 5' end of the genome somewhere between the primer binding site and the 5' end of the gag-coding region. These findings indicate that at least part of the sequence lost in the TK15 genome is indispensable for packaging viral genomic RNA into virions. TK15 induces nonvirus -producing 15c (-) transformants at high frequency. Southern blot analysis of DNAs from those 15c (-) clone cells revealed that TK15 -derived proviruses contained various extents of internal deletions. Many 15c (-) clones had a provirus carrying only the src gene with long terminal repeat sequences at both ends. The mechanism for the segregation of 15c (-) cells is discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6202881      PMCID: PMC254413     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Plaque assay for some strains of avian leukosis virus.

Authors:  S Kawai; H Hanafusa
Journal:  Virology       Date:  1972-04       Impact factor: 3.616

3.  The effects of reciprocal changes in temperature on the transformed state of cells infected with a rous sarcoma virus mutant.

Authors:  S Kawai; H Hanafusa
Journal:  Virology       Date:  1971-11       Impact factor: 3.616

4.  Isolation of different kinds of non-virus producing chick cells transformed by Schmidt-Ruppin strain (subgroup A) of Rous sarcoma virus.

Authors:  S Kawai; T Yamamoto
Journal:  Jpn J Exp Med       Date:  1970-08

5.  Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus.

Authors:  R Mann; R C Mulligan; D Baltimore
Journal:  Cell       Date:  1983-05       Impact factor: 41.582

6.  Nucleotide sequence of the 5' noncoding region and part of the gag gene of Rous sarcoma virus.

Authors:  R Swanstrom; H E Varmus; J M Bishop
Journal:  J Virol       Date:  1982-02       Impact factor: 5.103

7.  Characterization of a Rous sarcoma virus mutant defective in packaging its own genomic RNA: biological properties of mutant TK15 and mutant-induced transformants.

Authors:  S Kawai; T Koyama
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

8.  Identification of a sequence likely to be required for avian retroviral packaging.

Authors:  T Pugatsch; D W Stacey
Journal:  Virology       Date:  1983-07-30       Impact factor: 3.616

9.  Participation of subgenomic retroviral mRNAs in recombination.

Authors:  L H Wang; D W Stacey
Journal:  J Virol       Date:  1982-03       Impact factor: 5.103

10.  Encapsidation sequences for spleen necrosis virus, an avian retrovirus, are between the 5' long terminal repeat and the start of the gag gene.

Authors:  S Watanabe; H M Temin
Journal:  Proc Natl Acad Sci U S A       Date:  1982-10       Impact factor: 11.205

View more
  43 in total

1.  Human immunodeficiency virus types 1 and 2 differ in the predominant mechanism used for selection of genomic RNA for encapsidation.

Authors:  J F Kaye; A M Lever
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

2.  In vitro characterization of a base pairing interaction between the primer binding site and the minimal packaging signal of avian leukosis virus genomic RNA.

Authors:  Igor Kanevsky; Natalya Vasilenko; Hélène Dumay-Odelot; Philippe Fossé
Journal:  Nucleic Acids Res       Date:  2003-12-15       Impact factor: 16.971

3.  Characterization of unintegrated retroviral DNA with long terminal repeat-associated cell-derived inserts.

Authors:  M M Dunn; J C Olsen; R Swanstrom
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

4.  Mutations of RNA and protein sequences involved in human immunodeficiency virus type 1 packaging result in production of noninfectious virus.

Authors:  A Aldovini; R A Young
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

5.  Binding of human immunodeficiency virus type 1 (HIV-1) RNA to recombinant HIV-1 gag polyprotein.

Authors:  J Luban; S P Goff
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

6.  Molecular cloning and characterization of the RNA packaging-defective retrovirus SE21Q1b.

Authors:  D J Anderson; P Lee; K L Levine; J S Sang; S A Shah; O O Yang; P R Shank; M L Linial
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

7.  Specificity of retroviral RNA packaging.

Authors:  R Aronoff; M Linial
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

8.  Generation of a helper cell line for packaging avian leukosis virus-based vectors.

Authors:  P Savatier; C Bagnis; P Thoraval; D Poncet; M Belakebi; F Mallet; C Legras; F L Cosset; J L Thomas; Y Chebloune
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

9.  Frequent segregation of more-defective variants from a Rous sarcoma virus packaging mutant, TK15.

Authors:  M Nishizawa; T Koyama; S Kawai
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

10.  Mutational analysis of cis-acting packaging signals in human immunodeficiency virus type 1 RNA.

Authors:  J Luban; S P Goff
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.